These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 38785982)

  • 1. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
    Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.
    Siemionow M; Bocian K; Bozyk KT; Ziemiecka A; Siemionow K
    Stem Cell Rev Rep; 2024 Oct; 20(7):1819-1829. PubMed ID: 39017908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
    Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell transplantation-mediated dystrophin supplementation efficacy in Duchenne muscular dystrophy mouse motor function improvement demonstrated by enhanced skeletal muscle fatigue tolerance.
    Bourgeois Yoshioka CK; Takenaka-Ninagawa N; Goto M; Miki M; Watanabe D; Yamamoto M; Aoyama T; Sakurai H
    Stem Cell Res Ther; 2024 Sep; 15(1):313. PubMed ID: 39300595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
    Siemionow M; Ziemiecka A; Bożyk K; Siemionow K
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
    Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
    Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
    Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
    Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
    Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.
    Meng J; Sweeney NP; Doreste B; Muntoni F; McClure M; Morgan J
    Hum Gene Ther; 2020 Feb; 31(3-4):241-252. PubMed ID: 31801386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.
    Meng J; Counsell JR; Reza M; Laval SH; Danos O; Thrasher A; Lochmüller H; Muntoni F; Morgan JE
    Sci Rep; 2016 Jan; 6():19750. PubMed ID: 26813695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.